Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant study of personalized neoantigen mRNA vaccine RGL-270 plus adebrelimab in high-risk resected non-small cell lung cancer
CTR20261596Phase 2Active
- Sponsor
- Ruiling Pharmaceutical
- Start
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RGL-270, adebrelimab in non-small cell lung cancer (NSCLC), sponsored by Ruiling Pharmaceutical. Started Apr 2026; status: active.
02
Drugs
RGL-270adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261596.